<DOC>
	<DOCNO>NCT00888810</DOCNO>
	<brief_summary>The objective trial evaluate efficacy association topotecan lapatinib patient fail first line platinum-based chemotherapy within 12 month .</brief_summary>
	<brief_title>Efficacy Topotecan Lapatinib Early Recurrent Ovarian Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Age superior equal 18 year primitive ovarian adenocarcinoma histologically confirm peritoneal fallopian tube adenocarcinoma histologically confirm Progression relapse within 12 month end first line platin base chemotherapy association first line anticancer agent allow ( taxanes , anthracyclines , alkylants gemcitabine ) antiangiogenic ( bevacizumab , sunitinib ) . intraperitoneal chemotherapy first line possible No previous treatment HER inhibitor ( ex : gefitinib ) HER status necessary measurable lesion ( RECIST criterion ) . and/or CA125 value high 2 fold normal value CA125 high 2 fold nadir value ( normalize ) prove two sample distant 1 month OMS inferior equal 2. biological parameter follow : creatininemia ≤ 150 µmol/L clearance ≥ 50 mL/min , bilirubin ≤ 1,5 LNS , transaminases alcalin phosphatase ≤ 2 LNS without hepatic metastasis ≤ 3 LNS hepatic metastasis , neutrophils ≥ 1,5.109/L , plaquettes ≥ 100.109/L . normal FEV No previous treatment chemotherapy , hormonotherapy , immunotherapy radiotherapy within 4 week inclusion No concomitant treatment forbidden lapatinib . No previous treatment Amiodarone 6 month inclusion sign informed consent Previous treatment : intensive chemotherapy autograft two ligne chemotherapy previous total abdominal irradiation previous chemotherapy antiHER treatment History brain meningitis metastasis uncontrolled . Malignancies except adequately treat carcinoma situ cervix and/or basal cell skin cancer . uncontrolled infectious pathology uncontrolled cardiovascular disease Patients active intestinal occlusion permit oral treatment know hypersensibility topotecan excipients Woman childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period Individual deprive liberty</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>ovarian - cancer - relapse - topotecan - lapatinib</keyword>
</DOC>